ADICET BIO, INC. : Regulation FD Disclosure (form 8-K)

Published: 2022-05-05 07:08:10 ET ACET

Item 7.01 Regulation FD Disclosure.

On May 5, 2022, Adicet Bio, Inc. (the "Adicet") issued a press release titled "Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

99.1 Press release issued by Adicet Bio, Inc. on May 5, 2022, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).

--------------------------------------------------------------------------------